Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept and PRP vs Early Vitrectomy for Diabetic Vitreous Hemorrhage
NCT04153253Phase 4Completed
- Sponsor
- Al Hadi Hospital
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in vitreous hemorrhage secondary to proliferative diabetic retinopathy (DVH), sponsored by Al Hadi Hospital. Started Mar 2018; status: completed.
02
Drugs
aflibercept
03
Conditions
vitreous hemorrhage secondary to proliferative diabetic retinopathy (DVH)
Beyond the preview
Go deeper on NCT04153253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153253.